Insider buying last 90 days
No open-market insider purchases were filed for SUPN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SUPN insider filing, plotted on the chart in Gekko.Open SUPN in Gekko
NASDAQ: SUPN
Supernus Pharmaceuticals (SUPN) Stock Analysis & Forecast
Oct 12 close
$42.81+0.14 (+0.3%)
Gekko Brief
AI summaryOct 12 closeSupernus Pharmaceuticals this week drew attention on two fronts: FDA approval for ONAPGO, its Parkinson's disease treatment, which adds to the company's central nervous system portfolio, and continued progress on the proposed merger with Indivior. That merger process has included voluntarily updated joint proxy materials with additional valuation-related disclosures, following lawsuits alleging inadequate disclosures, and supplemental detail on Cantor Fitzgerald's valuation analyses, with a $1 billion Indivior dividend factoring into the proposed merger valuations.
SUPN closed at $42.81, up 0.3%, sitting below both its 50-day average of $44.30 and its 200-day average of $47.98, with the shorter average itself below the longer one. The GekkoIndex reads 59, placing the stock in the Neutral zone, down 1.2 over five periods. Price stands 37.1% below Gekko Fair Value of $68.04. Over the past year the stock is down 13.5%, with declines of 8.3% over three months and 14.3% over six months, though it has gained 2.8% over the past month.
Supernus next reports earnings on 3 November 2026 after close, 22 days away and within a typical 20-trading-day holding window; its last report showed EPS of $0.88 against an estimate of $0.41, with a 0.9% reaction, and it has beaten estimates in 7 of 8 recent quarters. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 5.1% gain over 5 years, rising in 3 of them.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Supernus Pharmaceuticals price vs fair value
Close $42.81200-day averageGekko Fair Value $68.04
Supernus Pharmaceuticals quick facts
- Market cap
- $2.48B
- P/E ratio
- —
- Forward P/E
- 20.2
- EPS, TTM
- −$1.92
- Revenue, TTM
- $830.4M
- Profit margin
- -13.2%
- Dividend yield
- —
- Beta
- 0.55
- Volume
- 914,563 avg 694,849
- 1-year return
- −13.5%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±6.2%
- 50-day average
- $44.30
- 200-day average
- $47.98
- Next earnings
- Nov 3 after close
- Shares outstanding
- 58.22M
Supernus Pharmaceuticals swing-trade checklist
Supernus Pharmaceuticals scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $42.81 is below the 50-day ($44.30) and 200-day ($47.98) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
59, Neutral
Reading 59 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
37.1% below
Price is 37.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.1% on average
From this point in the calendar, the next 20 trading days averaged +5.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Supernus Pharmaceuticals stock chart and price history
Supernus Pharmaceuticals closed at $42.81 on Oct 12, 2026, −13.5% over the past year, inside a 52-week range of $40.51 to $59.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.8%
- 3 months
- −8.3%
- 6 months
- −14.3%
- 1 year
- −13.5%
The full SUPN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SUPN in Gekko
Follow Supernus Pharmaceuticals through every session
Put SUPN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SUPN in GekkoFree for 7 days. No credit card required.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals focuses on creating and selling medicines for disorders affecting the brain and nervous system, marketed to patients across the United States. Its commercial lineup covers treatments for epilepsy and migraine prevention, ADHD in children and teenagers, and several products aimed at Parkinson's disease symptoms such as involuntary movement and periods of reduced mobility. It also markets a toxin-based therapy used for neck muscle spasms and excessive drooling in adults.
Alongside its approved treatments, the company runs a pipeline of experimental compounds at various stages of testing, including a combination drug and delivery device meant to head off mobility episodes in Parkinson's patients, early-stage epilepsy research, and a compound being studied for depression that has not responded to standard treatment. Additional candidates remain in preclinical work targeting other central nervous system conditions. Its medicines reach patients through pharmaceutical wholesalers, specialty pharmacies, and authorized distributors rather than direct sales.
Supernus Pharmaceuticals was founded in 2005 and is based in Rockville, Maryland. Its shares are listed on the NASDAQ under the ticker SUPN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- supernus.com
Supernus Pharmaceuticals GekkoIndex: the smart money zone
Supernus Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59, in the Neutral zone, down 1.2 points over five sessions.
59Neutral
Down 1.2 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 24 | +1.4% | +2.0% | ||
| Accumulation | 228 | +0.6% | +3.1% | ||
| Neutral (current zone) | 394 | +0.5% | +1.1% | ||
| Distribution | 33 | −1.9% | 0.0% | ||
| Selling | 3 | Too few readings yet | |||
Average SUPN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SUPN price, zone by zone.Track SUPN in Gekko
Is Supernus Pharmaceuticals stock overvalued? Gekko Fair Value
Supernus Pharmaceuticals trades 37.1% below Gekko Fair Value of $68.04, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Supernus Pharmaceuticals shares are worth, recalculated every trading day.
$68.04
Gekko Fair Value, Oct 10, 2026
37.1% Undervalued
At the end of Aug 2026 the price was 42.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SUPN in Gekko
Supernus Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Supernus Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SUPN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SUPN, plotted on the chart in Gekko.Open SUPN in Gekko
Supernus Pharmaceuticals earnings: next date and track record
Supernus Pharmaceuticals reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- $0.62
- Revenue estimate
- $218.3M
7 of 8reports beat the EPS estimate
±7.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Mar 3, 2026 AI summary
- What they said
- Supernus achieved record 2025 revenues of $719 million with 40% growth from four key products. The company completed an acquisition of Sage Therapeutics and launched ONAPGO for Parkinson's, generating $17.3 million in first-year sales. Qelbree exceeded $300 million in net sales with 26% growth, while GOCOVRI reached $146 million with 12% growth. ZURZUVAE contributed $53 million in collaboration revenues following the acquisition.
- Guidance
- Management expects Qelbree's gross-to-net percentage to remain at 50-55% in 2026. The company initiated a Phase IIb trial for SPN-820 in major depressive disorder with approximately 200 adult patients.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 3, 2026 | $0.88 est $0.41 | $211.6M est $195.2M | +0.9% |
| Nov 4, 2025 | $1.01 est $0.82 | $192.1M est $194.7M | −15.4% |
| Aug 5, 2025 | $0.91 est $0.47 | $165.5M est $168.2M | +14.5% |
| May 6, 2025 | $0.42 est $0.38 | $149.8M est $147.9M | −4.5% |
| Feb 25, 2025 | $0.55 est $0.52 | $174.2M est $155.3M | −2.4% |
| Nov 4, 2024 | $0.69 est $0.44 | $175.7M est $154.5M | +2.3% |
| Aug 6, 2024 | $0.36 est $0.31 | $168.3M est $148.9M | +14.3% |
| May 8, 2024 | $0.26 est $0.38 | $143.6M est $145.8M | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Supernus Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Supernus Pharmaceuticals is $61.75, +44.2% from the last close, from 3 firms rating the stock in the last 90 days.
$61.75consensus 12-month target, +44.2% from the last close
Now $42.81Avg $61.75
Low $60High $66
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Bank of America Securities | $60 | +40.2% |
| Aug 3 | TD Cowen | $65 | +51.8% |
| Jul 27 | Piper Sandler | $66 | +54.2% |
+1.1%average 20-day move after past Neutral readings
+5.1%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Supernus Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Supernus Pharmaceuticals averaged +5.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.2% | 4 of 5 |
| Next 10 trading days | +2.6% | 4 of 5 |
| Next 15 trading days | +4.4% | 4 of 5 |
| Next 20 trading days | +5.1% | 3 of 5 |
| Next 30 trading days | +5.4% | 3 of 5 |
For scale, SUPN’s typical 20-trading-day move in either direction is about 6.2%.
Supernus Pharmaceuticals market cap and key statistics
Supernus Pharmaceuticals’s market cap is $2.48B and revenue of $830.4M over the last twelve months.
Valuation
- Market cap
- $2.48B
- Forward P/E
- 20.2
- EPS, TTM
- −$1.92
- Gekko Fair Value
- $68.04
Trading
- Volume
- 914,563
- Avg volume, 20 days
- 694,849
- 52-week high
- $59.68
- 52-week low
- $40.51
- Shares outstanding
- 58.22M
Financials
- Revenue, TTM
- $830.4M
- Profit margin
- -13.2%
- Return on equity
- -10.5%
- Quarterly earnings growth, YoY
- +11.1%
Risk and income
- Beta
- 0.55
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±6.2%
Supernus Pharmaceuticals stock news this week
Coverage of Supernus Pharmaceuticals this week reads neutral: 1 positive, 4 neutral and 0 negative headlines.
- How Investors May Respond To Supernus Pharmaceuticals (SUPN) FDA Approval For ONAPGOSimply Wall Street, Oct 11
- Indivior, Supernus advance merger amid disclosure updatesThe Globe and Mail, Oct 8
- Supernus Pharmaceuticals, Inc. (SUPN) Stock forecastsYahoo Finance UK, Oct 7
- A $1B Indivior dividend factors into Supernus (SUPN) proposed merger valuations.Stock Titan, Oct 6
- Form 425 SUPERNUS PHARMACEUTICALS Filed by: SUPERNUS PHARMACEUTICALS, INC.StreetInsider, Oct 6
- Head-To-Head Contrast: Supernus Pharmaceuticals (NASDAQ:SUPN) and Shineco (NASDAQ:SISI)Defense World, Oct 5
Supernus Pharmaceuticals peers
Supernus Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Supernus Pharmaceuticals stock FAQ
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.48B at the Oct 12, 2026 close of $42.81, with 58.22M shares outstanding.
What is the Supernus Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Supernus Pharmaceuticals is $61.75, +44.2% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Supernus Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Supernus Pharmaceuticals is undervalued: the Oct 12, 2026 close of $42.81 is 37.1% below Gekko Fair Value of $68.04. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Supernus Pharmaceuticals report earnings next?
Supernus Pharmaceuticals is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of $0.62 per share on revenue of $218.3M. Supernus Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 7.3% on average across the report.
What is Supernus Pharmaceuticals’s 52-week high and low?
Supernus Pharmaceuticals’s 52-week high is $59.68 and its 52-week low is $40.51; it closed at $42.81 on Oct 12, 2026, −13.5% over the past year.
Is Supernus Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Supernus Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.